Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB009 plus Irinotecan in KRAS Wild-type Metastatic Colorectal Cancer
NCT01550055Phase 3Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- May 2009
- Primary completion
- Dec 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of recombinant anti-EGFR chimeric monoclonal antibody in metastatic colorectal cancer (mCRC), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Started May 2009; status: completed.
02
Drugs
recombinant anti-EGFR chimeric monoclonal antibody
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01550055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01550055.